文献速递肝病消化道肿瘤与早癌

台湾地区HBsAg和抗-HCV血清学阴性人群中血清HBcrAg与肝细胞癌的关联

Serum HBcrAg and Hepatocellular Carcinoma in a Taiwanese Population Seronegative for HBsAg and Anti-HCV.
PubMed 文献 · Clin Gastroenterol Hepatol · 2022-07-16

基于REVEAL-NBNC队列,纳入129例新发肝细胞癌病例和520例频数匹配的非肝癌对照,比较入组时血清HBcrAg及其他危险因素。基线HBcrAg阳性(≥1000 U/mL)在肝癌病例中占12.4%,显著高于对照的1.4%(P < .001);多因素分析中HBcrAg阳性与肝癌风险显著升高相关(校正OR 9.3,95%CI 3.3-26.4;P < .001)。结论认为HBcrAg血清阳性可能识别乙肝病毒流行区NBNC人群中肝癌高风险亚群。

要点

  • NBNC人群中基线HBcrAg阳性率肝癌病例12.4% vs 对照1.4%(P < .001)。
  • 校正后HBcrAg阳性与肝癌风险显著升高相关,OR 9.3(95%CI 3.3-26.4)。
  • HBcrAg阳性归因的肝癌比例为11.1%(95%CI 9.7%-12.5%)。

核心结论

  • HBcrAg血清阳性可能识别乙肝病毒流行区NBNC人群中肝癌风险较高的亚群。

研究设计与样本

  • 从REVEAL-NBNC队列中选取129例新发肝细胞癌病例和520例频数匹配的非肝癌对照,比较入组时血清HBcrAg及其他危险因素,采用回归分析估计OR和95%CI。

主要发现

  • 基线HBcrAg阳性(≥1000 U/mL)比例肝癌病例为12.4%,对照为1.4%,病例显著高于对照(P < .001)。
  • 多因素分析中HBcrAg阳性与肝癌风险显著升高相关,校正OR 9.3(95%CI 3.3-26.4;P < .001)。
  • HBcrAg阳性归因的肝癌比例为11.1%(95%CI 9.7%-12.5%)。

关键数值与推荐

  • HBcrAg阳性定义为≥1000 U/mL。
  • 肝癌病例基线HBcrAg阳性率12.4% vs 对照1.4%(P < .001)。
  • 校正OR 9.3(95%CI 3.3-26.4;P < .001)。
  • 归因比例11.1%(95%CI 9.7%-12.5%)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatitis B core-related antigen (HBcrAg) is a surrogate seromarker of intrahepatic hepatitis B virus covalently closed circular DNA quantity and activity and a predictor of hepatocellular carcinoma (HCC) in chronic hepatitis B patients. We assess association between HBcrAg and HCC in individuals seronegative for hepatitis B surface antigen and anti-hepatitis C virus (NBNC) in Taiwan. METHODS: A total of 129 newly developed HCC cases and 520 frequency-matched non-HCC controls were drawn from the REVEAL-NBNC cohort. Serum HBcrAg and other risk factors measured at recruitment were compared between cases and controls. Regression analysis was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: The proportion of baseline HBcrAg positivity (≥1000 U/mL) was significantly higher in HCC cases than in controls (12.4% vs 1.4%, P < .001). In multivariate analysis, HBcrAg positivity was associated with significantly higher risk of HCC (adjusted OR [95% CI]: 9.3 [3.3-26.4]; P < .001]. The HCC population attributable to HBcrAg positivity was 11.1% (95% CI: 9.7%-12.5%). CONCLUSIONS: Seropositivity of HBcrAg might identify a subset of the NBNC population at higher risk of HCC in hepatitis B virus endemic areas.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Hsieh YC, Pan MH, Jeng WJ, et al. Serum HBcrAg and Hepatocellular Carcinoma in a Taiwanese Population Seronegative for HBsAg and Anti-HCV. Clin Gastroenterol Hepatol. 2022. PMID: 35850414. doi:10.1016/j.cgh.2022.06.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。